Study for the effect of dapagliflozin combined with insulin pump in type 2 diabetes mellitus

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800018292

Enrollment

Unknown

Registered

2018-09-10

Start date

2018-05-01

Completion date

Unknown

Last updated

2018-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Group 1:dapagliflozin 10mg/d+ insulin pump + Saxagliptin 5mg/d or Liraglutide 1.2mg/d

Group 2:insulin pump + Saxagliptin 5mg/d or Liraglutide 1.2mg/d.

Eligibility

Sex/Gender

All

Age

20 Years to 79 Years

Inclusion criteria

Inclusion criteria: Aged from 20 to 79 years; subcutaneous insulin hypoglycemic therapy lasted for more than 12 weeks; glycosylated hemoglobin (HbA1c) > 7%; combined use of saglistine or liraglutide for more than 12 weeks; glomerular filtration rate (eGFR) > 45 ml / min / 1.73 m2; eligible subjects agreed to be hospitalized for insulin pump hypoglycemic therapy After one week of glucose treatment, the insulin pump was withdrawn and subcutaneous insulin was injected or even discontinued.

Exclusion criteria

Exclusion criteria: Acute complications of diabetes, infection, tumor, primary liver disease and non-diabetic nephropathy. Cardiovascular and cerebrovascular events (acute coronary syndrome, unstable angina, acute myocardial infarction, acute stroke or transient ischemic events) occurred within 2 months.

Design outcomes

Primary

Measure	Time frame
Glycated hemoglobin;	—

Countries

China

Contacts

Public ContactGUO Li-Ting

Teda International Cardiovascular Hospital

guolt0323@163.com+86 13820797731

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026